

**BIRLA INSTITUTE OF TECHNOLOGY, MESRA, RANCHI
(END SEMESTER EXAMINATION)**

**CLASS: MPHARM
BRANCH: PHARMACY**

**SEMESTER: 1st
SESSION: MO 2025**

SUBJECT: MPH102T DRUG DELIVERY SYSTEM

TIME: 3.00 Hours

FULL MARK: 75

INSTRUCTIONS:

1. The missing data, if any, may be assumed suitably.
2. Before attempting the question paper, be sure that you have got the correct question paper.
3. Tables/Data hand book/Graph paper etc. to be supplied to the candidates in the examination hall.
5. Answer any five questions.

- 1a. Discuss the characteristics of drugs that are not suitable for peroral sustained release forms. Discuss the drug parameters to be considered for sustained delivery dosage forms [7]
- 1b. Discuss in details about Osmotic pressure activated systems. Discuss with graphical representation the working of a membrane and matrix system w.r.t drug release. [8]

- 2a. Explain the working principle of Bioerosion regulated and Bioresponsive drug delivery systems. Discuss the working principle of magnetically controlled drug delivery systems [7]
- 2b. Discuss in details with diagrams Hydrodynamic pressure activated systems and Vapour Pressure activated systems. [8]

- 3a. Discuss the barriers for ocular delivery w.r.t Cornea, Noncorneal, BAB and BRB [7]
- 3b. Discuss the approaches for improving ocular bioavailability. [8]

- 4a. Discuss the different Approaches for formulating GRRDS in details [7]
- 4b. Discuss the barriers for buccal delivery and also the approaches for effective buccal delivery [8]

- 5a. Explain the structure of the skin and the barriers it presents to transdermal drug delivery. How do these barriers influence the design of transdermal drug delivery systems? [7]
- 5b. Discuss the role of penetration enhancers in transdermal drug delivery systems. Describe the formulation approaches and evaluation methods used for designing effective transdermal patches [8]

- 6a. Explain the various barriers faced in the delivery of proteins and peptides. How do these barriers affect their bioavailability and therapeutic efficacy? [7]
- 6b. Discuss the formulation strategies for protein and peptide delivery systems. Describe the evaluation methods used to assess the effectiveness protein and peptides. [8]

- 7a. Discuss the advantages and disadvantages of transdermal techniques used for the delivery of vaccines. [7]
- 7b. Explain in detail the design and mechanism of microneedle-assisted vaccine delivery. [8]

:::20/11/2025:::M